Covid-19 ba.2.86 variant
Pro Research Analysisby 
Searched over 200M research papers
BA.2.86 Variant Emergence and Global Spread
The BA.2.86 variant, also known as "Pirola," is a subvariant of SARS-CoV-2 that has attracted significant attention due to its high number of mutations, particularly in the spike protein. It was first identified in Denmark in July 2023 and has since been detected in multiple countries, including Israel, the United Kingdom, the United States, and South Africa, with cases appearing to be unconnected, indicating community transmission in some regions Looi2023Satapathy2024Lambrou2023+1 MORE.
Genetic Mutations and Spike Protein Changes
BA.2.86 carries over 30 mutations in its spike protein compared to earlier Omicron subvariants, with some mutations potentially enhancing its ability to evade immune responses. Notably, it shares several mutations with previous variants but also has unique changes, such as P681R and F486P, which may influence its infectivity and interaction with human cells . These mutations are important because the spike protein is the main target for vaccines and therapies .
Immune Evasion and Vaccine Effectiveness
Despite its many mutations, BA.2.86 is less immune evasive than some other recent variants, such as the XBB sublineages and CH.1.1. Studies show that while BA.2.86 can reduce the effectiveness of neutralizing antibodies from previous infection or vaccination, it does not show significantly increased resistance compared to XBB.1.5 Qu2024Wang2023Qu2023+3 MORE. Importantly, updated multivalent vaccines, such as the tetravalent SCTV01E booster, have been shown to induce strong neutralizing responses against BA.2.86 and other emerging variants .
T cell responses, which are another important part of the immune system, appear to remain robust against BA.2.86, suggesting that widespread loss of T cell recognition is unlikely, even with the new mutations .
Infectivity, Transmission, and Pathogenicity
Laboratory studies indicate that BA.2.86 has relatively high infectivity and fusogenicity in certain cell types, which could affect how easily it spreads or causes disease. However, its overall fitness and pathogenicity are not necessarily higher than previous variants, and there is currently no evidence that BA.2.86 leads to more severe illness Qu2024Qu2023Scarpa2023+1 MORE.
Surveillance and Public Health Response
The emergence of BA.2.86 highlights the importance of ongoing genomic surveillance and rapid data sharing. Early detection was made possible by a combination of genomic, wastewater, and traveler-based surveillance systems, which allowed for real-time tracking of the variant’s spread Satapathy2024Lambrou2023Scarpa2023. Continued monitoring is essential to assess the impact of BA.2.86 and to guide public health responses, including vaccine updates and other interventions Satapathy2024Lambrou2023Scarpa2023.
Conclusion
BA.2.86 is a highly mutated SARS-CoV-2 subvariant that has spread to multiple countries and shows some ability to evade immune responses. However, it is less immune evasive than some other recent variants, and current multivalent vaccines remain effective. There is no evidence so far that BA.2.86 causes more severe disease. Ongoing surveillance and research are crucial to understanding and managing the risks posed by this and future variants.
Sources and full results
Most relevant research papers on this topic